I'm interested in

General MM

Quick poll

Multiple myeloma diagnosis in primary care

Multiple myeloma diagnosis in primary care

Closes Aug 15, 2018

General MM

Quick poll

What is monoclonal gammopathy of clinical significance?

Closes Aug 14, 2018

General MM

Quick poll

PSMB5 mutations described for the first time in multiple myeloma…

Closes Aug 7, 2018

General MM

Quick poll

SRF231 is granted orphan designation status for the treatment of multiple…

SRF231 is granted orphan designation status for the treatment of multiple myeloma

Closes Jul 31, 2018

General MM

Quick poll

A retrospective study of early-onset multiple myeloma

Closes Jul 31, 2018

Patients eligible for transplant, General MM, Patients non-eligible for transplant,

Quick poll

Double-Hit: a subgroup of high-risk newly diagnosed multiple myeloma…

Closes Jul 30, 2018

General MM, Patients non-eligible for transplant

Quick poll

The CHMP recommends daratumumab as front-line treatment

The CHMP recommends daratumumab as front-line treatment

Closes Jul 30, 2018 ,

General MM

Quick poll

Fast Track designation granted for galinpepimut-S

Closes Jul 25, 2018

Quick poll

NICE rejects daratumumab (darzalex) for use second-line with bortezomib…

Closes Jul 17, 2018

Relapsed/refractory patients

Quick poll

EHA 2018 | Pomalidomide/dexamethasone with or without elotuzumab: the…

EHA 2018 | Pomalidomide/dexamethasone with or without elotuzumab: the ELOQUENT-3 trial

Closes Jul 16, 2018

General MM

Quick poll

EHA 2018 | Preclinical study to assess dual BCL-2 and MCL-1 inhibition in…

Closes Jul 11, 2018 ,

Quick poll

EHA 2018| Phase I/IIa study of MOR202 used in combination treatments

Closes Jul 8, 2018 ,

Relapsed/refractory patients

Quick poll

EHA 2018 | Preclinical data for BCMAxCD3 bi-specific antibody JNJ-957

EHA 2018 | Preclinical data for BCMAxCD3 bi-specific antibody JNJ-957

Closes Jul 6, 2018

General MM

Quick poll

EHA 2018 | Phase Ib study of isatuximab in combination with pomalidomide…

Closes Jul 4, 2018

Relapsed/refractory patients

Quick poll

EHA 2018 | The phase III OPTIMISMM study of pomalidomide, bortezomib and…

Closes Jun 28, 2018 ,

A global online educational platform sharing the latest research and emerging treatment information in multiple myeloma

Latest Medical Information

Latest Congress Coverage

English & German

Relapsed/refractory patients

Katja Weisel | EHA 2018 | Turning the tide after relapse: managing relapsed MM

Jun 19, 2018

English & German

General MM,Patients non-eligible for transplant,Patients eligible for transplant

Hermann Einsele | EHA 2018 | New concepts in consolidation for patients with NDMM

Jun 19, 2018

Patients eligible for transplant,Patients non-eligible for transplant

Charlotte Pawlyn | EHA 2018 | Results from Myeloma XI trial

Jun 18, 2018

Latest Biology

General MM

PSMB5 mutations described for the first time in multiple myeloma patients

Aug 7, 2018

General MM

KDM1A is first identified germline MM predisposition gene

May 3, 2018

General MM

Detection of MM-associated translocations and mutations in IGLL5

Apr 17, 2018

Latest Drug Updates

General MM

SRF231 is granted orphan designation status for the treatment of multiple myeloma

Jul 31, 2018

General MM,Patients non-eligible for transplant

The CHMP recommends daratumumab as front-line treatment

Jul 30, 2018 , Expert Opinion

General MM

Fast Track designation granted for galinpepimut-S

Jul 25, 2018

Where we are next

European School of Haematology (ESH) 4th International Conference on Multiple Myeloma

October 5–7, 2018 | Mandelieu, FR

The MM Hub will be attending the European School of Hematology (ESH) 4th International Conference on Myeloma, to be held in Mandelieu, France, from 5-7 October 2018. The meeting will be chaired by Kenneth C. Anderson, Maria Victoria Mateos, and Philippe Moreau, and will take place in the Congress Mandelieu Expo Center. The meeting attracts world-class leaders who present the latest clinical data and debate important and contentious issues in MM.
#mmsm

Event Website

Map data ©2018 Google

Map data ©2018 Google

Report a map error

Connect with us

Our sister hubs

Visit our other community physician education hubs in haematology and oncology

Professional society

The European School of Haematology (ESH) is a not-for-profit institution for continuing education founded in 1985 to promote and facilitate access to state-of-the-art and cutting-edge knowledge in haematology and related disciplines at the European level. ESH Conferences present state-of-the-art science and insight into new developments in the fields of basic, clinical and therapeutic research in Haematology.

Our supporters

Bronze

Contributor